Codagenix

Codagenix is a later-stage private company working in the vaccine and cancer virotherapeutic space using a machine learning platform to rationally redesign viral genomes to reduce viral gene function. Their most advanced program is an intranasal COVID vaccine currently in a Phase 3 trial sponsored by the World Health Organization. Other clinical-stage programs include RSV, which recently reveived FDA Breakthrough Designation, and universal influenza, along with an IND-ready oncolytic virus, and preclinical programs in dengue and yellow fever.